{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-019084","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.758252+00:00","generated_at":"2026-06-25T21:46:43.203987+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Prelude Q1 net loss $29.5M ($0.63/sh); cash $266.2M funds into 2H2024; on track for data readouts in 2H2022","bullets":["Net loss $29.5M ($0.63/sh) vs $21.3M ($0.47) YoY; R&D expense $22.8M ($16.5M) on increased clinical activity.","Cash & equivalents $266.2M as of March 31, 2022, expected to fund operations into second half 2024.","PRMT5 program (PRT811) expansion cohort data analysis ongoing; next steps decision in 2H2022.","MCL1 inhibitor PRT1419 IV formulation prioritized; combination cohorts expected by mid-2022.","Jane Huang appointed President and CMO effective April 4, 2022; previously CMO Hematology at BeiGene."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-019084","json":"https://secwatch.observer/filing/0001564590-22-019084.json","markdown":"https://secwatch.observer/filing/0001564590-22-019084.md","text":"https://secwatch.observer/filing/0001564590-22-019084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000156459022019084/0001564590-22-019084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000156459022019084/prld-8k_20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:46:43.203987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}